Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients
Journal of the Formosan Medical Association · 2024
DOI: 10.1016/j.jfma.2023.07.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Formosan Medical Association, 2024. Verfasst von Ning-Chun Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taiwan. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Peripheral. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chang Gung Memorial Hospital.
Abstract (Originalsprache)
PURPOSE: We aimed to explore the clinical outcomes and prognostic factors for PTCL-NOS patients in the real world. METHODS: Clinical data were retrospectively collected from adult patients with PTCL-NOS treated at a single center in Taiwan. RESULTS: 104 PTCL-NOS patients with a median age of 53.0 years were enrolled. Patients with the International Prognostic Index (IPI) or prognostic index for peripheral T-cell lymphoma (PIT) scores of zero had a longer overall survival (OS) and progression free survival (PFS), while patients with IPI or PIT scores ≥1 did poorly. For patients who are eligible for transplantation, the use of pralatrexate as salvage chemotherapy has shown better OS (2-year OS 83.3% vs. 24.4%, P = 0.011) compared to patients who did not. By multivariate analysis, age >60 years, male, B symptoms, ECOG >1, lung involvement, and thrombocytopenia were independent adverse factors for OS. Incorporating factors in multivariate analysis, we established a novel predictive index for PTCL-NOS which efficiently stratifies patients into low (0-1 factor), intermediate-1 (2 factors), intermediate-2 (3 factors), and high risk (4-6 factors) groups with 2-year OS rates of 81.5%, 32.9%, 8.8%, and 0%, respectively (P < 0.001). CONCLUSION: PTCL-NOS patients have a dismal prognosis in Taiwan. Novel agents may improve the outcomes of PTCL-NOS patients. The usefulness of the novel prognostic index for PTCL-NOS needs further validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taiwan.
- Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan.
- College of Medicine, Chang Gung University, Taoyuan, Taiwan; Department of Anatomic Pathology, Chang Gung Memorial Hospital at Linkou, Taiwan.
- Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taiwan. Electronic address: hsiaowen@cgmh.org.tw.
Förderung
- Chang Gung Memorial Hospital
Zitieren
APA
Chen, N. C., Chang, H., Kuo, M. C., Lin, T. L., Shih, L. Y., Chuang, W. Y., & Kao, H. W. (2024). Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients. Journal of the Formosan Medical Association. https://doi.org/10.1016/j.jfma.2023.07.014
Vancouver
Chen NC, Chang H, Kuo MC, Lin TL, Shih LY, Chuang WY, et al. Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients. Journal of the Formosan Medical Association. 2024. doi:10.1016/j.jfma.2023.07.014
BibTeX
@article{Chen2024,
author = {Chen, Ning-Chun and Chang, Hung and Kuo, Ming-Chung and Lin, Tung-Liang and Shih, Lee-Yung and Chuang, Wen-Yu and Kao, Hsiao-Wen},
title = {Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients},
journal = {Journal of the Formosan Medical Association},
year = {2024},
doi = {10.1016/j.jfma.2023.07.014}
}
EUVIMED